Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Touchlight Genetics Ltd
Touchlight Genetics Ltd
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
IMPACT CKD model reveals the escalating toll of chronic kidney disease
The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Isospec Analytics launches biomolecular analysis technology to identify unknown molecules
The novel technology optimises the identification process of unknown molecules compared to mass analysis
Building strong foundations for a resilient and planet-friendly future
Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector
The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Research & Development
Touchlight’s dbDNA to be used in neoantigen cancer vaccine trial
The dbDNA technology will be used in the development of a non-small cell lung cancer vaccine
Cell & Gene Therapy
Touchlight awarded tender to supply enzymatic dbDNA to CPI
CPI has selected Touchlight to supply research and GMP-grade enzymatic DNA for the development and manufacturing of RNA therapeutics and vaccines
Research & Development
Curia expands biologics capabilities with access to Touchlight’s doggybone DNA
Curia collaborates with Touchlight to expand its mRNA manufacturing offering to enable access to enzymatic doggybone DNA (dbDNA)
Manufacturing
Touchlight creates giant London DNA manufacturing facility
Facility will have capacity that exceeds today’s global plasmid DNA demand and can enable commercialisation of genetic medicines
Regulatory
FDA signs off Touchlight's Drug Master File
The acceptance of the DMF for GMP grade dbDNA will ensure that customers no longer need to prepare a standalone section in their fillings
Digital
Touchlight signs DNA technology license agreement with Voyager
Touchlight’s enzymatically amplified doggybone DNA technology enables the rapid and scalable amplification of DNA regardless of sequence length or complexity
Manufacturing
Lonza announces Touchlight collaboration on end-to-end mRNA
Lonza will have the ability to integrate an additional source of DNA in its end-to-end offering to customers developing messenger RNA therapeutics and vaccines
Subscribe now